Ophthalmology Clinical Research Capabilities
WCCT Global offers an end-to-end solution for conducting Phase I-II ophthalmic clinical trials. WCCT combines site ownership with a network of ophthalmology research centers, investigators, and KOLs to provide its partners the experience and services necessary to accelerate the development of new treatments. Since 2006, WCCT has performed over 35 clinical trials in the area of ophthalmology.
Clinical Development Highlights
Has served as a partner from Phase 1 through Phase 3 trials in the following indications:
- Open-Angle Glaucoma
- Ocular Hypertension
- Dry Eye Disease
- Corneal Disorders
Our team members have firsthand clinical knowledge of ophthalmic indications, the investigational agents being studied, and a true clinical understanding of the disease states.
WCCT maintains numerous partnerships with KOLs and key-collaborating research sites across the country. With 10+ sites in southern CA and another 20+ sites throughout the U.S., WCCT brings together a breadth of ophthalmic specialists with access to a variety of patients and combines this with our depth of knowledge in early clinical development.
Additionally, WCCT’s Clinical Pharmacology Unit (CPU) is located near Los Angeles, CA, providing access to an ethnically diverse population of ophthalmology patients, particularly for early phase ethnobridging and proof of concept trials. WCCT’s 180-bed CPU in Cypress, CA is capable of conducting various ophthalmic procedures and assessments in-house including: BCVA, slit lamp examination, lens opacification, IOP measurement, gonioscopy, specular microscopy, and more.
WCCT recently completed a Phase II Dry Eye Disease trial that enrolled 336 patients across 12 investigational sites. Enrollment was completed in less than 3 months, beating the planned clinical timelines by 33%.